• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform

tetano

Editor, Senior Moderator
Vaccine. 2013 Jul 20. pii: S0264-410X(13)00948-1. doi: 10.1016/j.vaccine.2013.07.021. [Epub ahead of print]
Self-adjuvanting influenza candidate vaccine presenting epitopes for cell-mediated immunity on a proteinaceous multivalent nanoplatform.
Szurgot I, Szolajska E, Laurin D, Lambrecht B, Chaperot L, Schoehn G, Chroboczek J.
Source

Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02106 Warsaw, Poland. Electronic address: inga@ibb.waw.pl.
Abstract

We exploit the features of a virus-like particle, adenoviral dodecahedron (Ad Dd), for engineering a multivalent vaccination platform carrying influenza epitopes for cell-mediated immunity. The delivery platform, Ad Dd, is a proteinaceous, polyvalent, and biodegradable nanoparticle endowed with remarkable endocytosis activity that can be engineered to carry 60 copies of a peptide. Influenza M1 is the most abundant influenza internal protein with the conserved primary structure. Two different M1 immunodominant epitopes were separately inserted in Dd external positions without destroying the particles' dodecahedric structure. Both kinds of DdFluM1 obtained through expression in baculovirus system were properly presented by human dendritic cells triggering efficient activation of antigen-specific T cells responses. Importantly, the candidate vaccine was able to induce cellular immunity in vivo in chickens. These results warrant further investigation of Dd as a platform for candidate vaccine, able to stimulate cellular immune responses.

Copyright ? 2013. Published by Elsevier Ltd.
KEYWORDS:

APC, Ad, Ad3, Adenoviral dodecahedron, CTL, Cell-mediated immunity, Dd, FCS, HA, HLA, Influenza vaccine, M1 immunodominant epitopes, MoDC, NA, PBMC, PE, PMA/Iono, Pb, SPF, VLP, Virus-like particle, aa, adenovirus, adenovirus serotype 3, amino acid, antigen-presenting cells, cytotoxic T lymphocyte, dodecahedron, fetal calf serum, hemagglutinin, human leukocyte antigen (a group of the most important antigens responsible for tissue compatibility), monocyte-derived dendritic cells, neuraminidase, pDC, penton base protein, peripheral blood mononuclear cells, phorbol 12-myristate 13-acetate/ionomycin, phycoerythrin, plasmacytoid dendritic cells, recombinant wild-type Dd, rwtDd, specific pathogen-free, virus-like particle

PMID:
23880363
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23880363
 
Back
Top Bottom